DataSheet_1_Non-Ablative Chemotherapy Followed by HLA-Mismatched Allogeneic CD3+ T-Cells Infusion Causes An Augment of T-Cells With Mild CRS: A Multi-Centers Single-Arm Prospective Study on Elderly Acute Myeloid Leukemia and int-2/High Risk Myelodysplastic Syndrome Patients.docx
To evaluate the efficacy and safety of standard or low-dose chemotherapy followed by HLA-mismatched allogeneic T-cell infusion (allo-TLI) for the treatment of elderly patients with acute myeloid leukemia (AML) and patients with intermediate-2 to high-risk myelodysplastic syndrome (MDS).
MethodsWe carried out a prospective, multicenter, single-arm clinical trial. Totally of 25 patients were enrolled, including 17 AML patients and 8 MDS patients. Each patient received four courses of non-ablative chemotherapy, with HLA-mismatched donor CD3+ allo-TLI 24 h after each course. AML patients received chemotherapy with decitabine, idarubicin, and cytarabine, and MDS patients received decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor.
ResultsA total of 79 procedures were performed. The overall response rates of the AML and MDS patients were 94% and 75% and the 1-year overall survival rates were 88% (61–97%) and 60% (13–88%), respectively. The overall 60-day treatment-related mortality was 8%. Compared with a historical control cohort that received idarubicin plus cytarabine (3 + 7), the study group showed significantly better overall response (94% vs. 50%, P=0.002) and overall survival rates (the 1-year OS rate was 88% vs. 27%, P=0.014). Post-TLI cytokine-release syndrome (CRS) occurred after 79% of allo-TLI operations, and 96% of CRS reactions were grade 1.
ConclusionElderly AML patients and intermediate-2 to high-risk MDS patients are usually insensitive to or cannot tolerate regular chemotherapies, and may not have the opportunity to undergo allogeneic stem cell transplantation. Our study showed that non-ablative chemotherapy followed by HLA-mismatched allo-TLI is safe and effective, and may thus be used as a first-line treatment for these patients.
Clinical Trial Registrationhttps://www.chictr.org.cn/showproj.aspx?proj=20112.
History
References
- https://doi.org//10.1158/1078-0432.CCR-10-0415
- https://doi.org//10.1002/ijc.31753
- https://doi.org//10.1038/nature10673
- https://doi.org//10.1126/science.aar4060
- https://doi.org//10.1016/S0140-6736%2820%2932334-5
- https://doi.org//10.1126/science.aar6711
- https://doi.org//10.1126/science.aaa4967
- https://doi.org//10.1002/cncr.30491
- https://doi.org//10.1056/NEJMoa1709919
- https://doi.org//10.1182/blood-2016-04-703751
- https://doi.org//10.1038/sj.bmt.1701771
- https://doi.org//10.1038/sj.bmt.1702726
- https://doi.org//10.1001/jamaoncol.2017.2656
- https://doi.org//10.1182/blood-2010-06-288506
- https://doi.org//10.5966/sctm.2015-0196
- https://doi.org//10.1182/blood-2001-12-0354
- https://doi.org//10.1111/j.1365-2141.2009.07604.x
- https://doi.org//10.1200/JCO.2011.40.3642
- https://doi.org//10.1056/NEJMoa0901409
- https://doi.org//10.3238/arztebl.2011.0863
- https://doi.org//10.3390/cancers12020357
- https://doi.org//10.1056/NEJMra0902908
- https://doi.org//10.1182/blood.V89.6.2079
- https://doi.org//10.1002/ajh.23174
- https://doi.org//10.1182/blood-2016-03-643544
- https://doi.org//10.1182/blood-2009-03-209262
- https://doi.org//10.1182/blood.v99.12.4618
- https://doi.org//10.1038/s41598-019-40244-y
- https://doi.org//10.1002/ajh.20693
- https://doi.org//10.1200/JCO.2003.04.036
- https://doi.org//10.1182/blood-2005-10-4149
- https://doi.org//10.1046/j.1365-2141.1997.1112925.x
- https://doi.org//10.1182/blood-2014-05-552729
- https://doi.org//10.1016/S2352-3026%2818%2930132-7
- https://doi.org//10.1080/10428194.2018.1443328
- https://doi.org//10.1200/JCO.2012.42.0281
- https://doi.org//10.1007/s00432-016-2331-0
- https://doi.org//10.1007/s11899-017-0361-6
- https://doi.org//10.1111/trf.12524
- https://doi.org//10.1007/s00277-018-3453-z
- https://doi.org//10.1002/ajh.25769
- https://doi.org//10.1007/s11912-019-0823-1
- https://doi.org//10.1002/hon.2755
- https://doi.org//10.1002/ajh.25978
- https://doi.org//10.1016/j.leukres.2007.02.009
- https://doi.org//10.3109/10428194.2014.963074
- https://doi.org//10.1016/j.leukres.2009.08.010
- https://doi.org//10.19746/j.cnki.issn.1009-2137.2019.02.030
- https://doi.org//10.1016/S2352-3026%2819%2930114-0
- https://doi.org//10.1200/JCO.2016.70.7349
- https://doi.org//10.1016/S0140-6736%2898%2911135-2
- https://doi.org//10.1016/j.bbmt.2008.10.025
- https://doi.org//10.1182/blood-2009-07-231092
- https://doi.org//10.18632/oncotarget.17241
- https://doi.org//10.1002/ajh.26061
- https://doi.org//10.1016/j.bbmt.2017.01.085
- https://doi.org//10.1002/ajh.25781
- https://doi.org//10.1002/stem.5530120405
- https://doi.org//10.1016/0140-6736%2890%2992206-w
- https://doi.org//10.1182/blood.V80.10.2479.2479
- https://doi.org//10.1182/blood.V81.4.901.901
- https://doi.org//10.1016/j.bbmt.2008.12.503
CC BY 4.0